Trusted Resources: Education
Scientific literature and patient education texts
Recent Advances in the Noninvasive Strategies of Cardiac Amyloidosis
source: Heart Failure Reviews
year: 2016
authors: Zhao L, Fang Q
summary/abstract:The heart, like any organ in the body, is susceptible to amyloid deposition. Although more than 30 types of protein can cause amyloidosis, only two types commonly deposit in the ventricular myocardium: amyloid light chain and amyloid transthyretin.
Amyloid cardiomyopathy is usually a major determinant of patient outcomes, and the diagnosis of heart involvement can be often relatively under-diagnosed, owing to nonspecific presenting symptoms and signs at a subclinical stage.
The diagnosis of cardiac amyloidosis is usually performed by endomyocardial biopsy; however, the invasive nature and related high-risk complications restrict its wide use in clinical settings. Recently, with the advent of innovative techniques used for evaluating cardiac amyloidosis, noninvasive methods become increasingly important, especially in earlier diagnosis, distinguishing typing, risk prediction and response to treatment. Here, we will review recent developments in the noninvasive methods used in the assessment of cardiac amyloidosis, focused on the laboratory biomarkers and imaging modalities.
organization: Peking Union Medical College and Chinese Academy of Medical Sciences, ChinaDOI: 10.1007/s10741-016-9580-5
read more full text
Related Content
-
Cardiac Amyloidosis Program at Brigham and Women’s HospitalThe Cardiac Amyloidosis Program at Brigh...
-
Wild Type ATTR Amyloidosis (Senile Systemic Amyloidosis)Amyloidosis is a rare disease caused by ...
-
Managing Physical Side EffectsCancer and cancer treatment often cause ...
-
Inotersen Treatment for Patients With Hereditary Transthyretin AmyloidosisBackground: Hereditary transthyretin am...
-
Anuj Mahindra, MDAnuj Mahindra is a hematologist and medi...
-
ATTR Treatment Chart – ASG Webinar 7.15.23 – 1/7https://www.youtube.com/watch?v=UcxmPgZ7...
-
Janssen Submits Application Seeking U.S. FDA Approval of DARZALEX FASPRO™ (Daratumumab and Hyaluronidase-fihj) for...The Janssen Pharmaceutical Companies of ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.